CD19/CD22 bispecific, cocktail and sequential CAR-T therapies exhibit great efficacy in B-ALL patients, especially for patients with relapse after CD19-related immunotherapy [22–24]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.